Integrating the inputs that shape pancreatic islet hormone release. [PDF]
, 2019 The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
International Journal of Endocrinology, 2015 The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang +4 more
doaj +1 more source
Glucagon Receptor Signaling and Lipid Metabolism
Frontiers in Physiology, 2019 Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic ...
Katrine D. Galsgaard +11 more
doaj +1 more source
Experimental and clinical pharmacology - Incretin mimetics and enhancers: mechanisms of action [PDF]
, 2008 The incretins are peptide hormones secreted from the gut in response to food. They increase the secretion of insulin. The incretin response is reduced in patients with type 2 diabetes, so drugs acting on incretins may improve glycaemic control. Incretins
Prins, Johannes B.
core +1 more source
Сахарный диабет, 2018 Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications.
Nina A. Petunina, Milena Е. Telnova
doaj +1 more source
Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. [PDF]
, 2019 Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions ...
Akiba, Yasutada +2 more
core
Journal of Anesthesia, Analgesia and Critical CareGlucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno +6 more
doaj +1 more source
Journal of DiabetologyA novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj +1 more source
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]
, 2020 Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea +6 more
core +2 more sources